Sanofi (SAN) Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis

Press Release: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
– Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
– Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trial
– Long-term safety data from a 52-week open-label extension trial in this age group …

Read the source article at Financial Research & Reports Finder
2022-06-08 00:50:00